Amgen Inc.: SWOT Analysis & Company Profile by BusinessReview

VIEWS: 166 PAGES: 26

Business Review’s Amgen Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.

More Info
									Amgen Inc.

_________________________________________________________________________________




Amgen Inc.: SWOT Analysis & Company
Profile


Reference code: BRPH021CP10-Q4

Published: Jun 2010




Business Review
John Carpenter House
7 Carmelite Street
London EC4Y 0BS
United Kingdom
Tel: +44 (0) 20 7936 6400
Fax: +44 (0) 20 7336 6813



___________________________________________________________________________________________

Amgen Inc. - SWOT Profile                                                           Page 1
Amgen Inc.

__________________________________________________________________________________________


Amgen Inc. - Company Overview

Amgen Inc. (Amgen) is a biotechnology company focusing on discovering, developing, manufacturing and marketing
human therapeutics based on advances in cellular and molecular biology. The company markets therapeutic products in
the field of supportive cancer care, nephrology and inflammation. The company focuses on research and development
(R&D) activities to develop novel human therapeutics in the areas of oncology, hematology, inflammation, bone,
nephrology and general medicine. Amgen principally operates in the US, Canada, Europe, Australia and Asia. The
company is headquartered in California, the US.


Financial Performance

The company reported revenues of (U.S. Dollars) USD 14,642.00 million during the fiscal year ended December 2009, a
decrease of 2.41% from 2008. The operating profit of the company was USD 5,506.00 million during the fiscal year 2009,
an increase of 5.60% over 2008. The net profit of the company was USD 4,605.00 million during the fiscal year 2009, an
increase of 13.65% over 2008.




Amgen Inc. - Key Facts

Amgen Inc., Key Facts

                                  One Amgen Center Drive,

Corporate Address:                Thousand Oaks, California (CA), Ticker Symbol, Stock            AMGN (NASDAQ)
                                                                    Exchange
                                  91320, United States


Telephone                         + 1 805 4471000                   No. of Employees              17,000



Fax                               + 1 805 4471010                   Financial Year End            December



URL                               www.amgen.com                     Revenue (in USD Million)      14,642.00


                                  Medical Equipment ,
Industry                          Pharmaceuticals and Healthcare

                                  Australia, Hong Kong Special Administrative Region of China, India, Japan, New Zealand, Austria,
                                  Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy,
Locations                         Lithuania, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland, United
                                  Kingdom, Canada, United States, Brazil, Mexico
Source: Annual Report, Company Website, Primary and Secondary Research




___________________________________________________________________________________________

Amgen Inc. - SWOT Profile                                                                                                 Page 2
Amgen Inc.

__________________________________________________________________________________________


Amgen Inc. - Business Description

Amgen Inc. (Amgen) is a US-based global biotechnology company that provides innovative human therapeutics. The
company focuses on research, development, manufacture and commercialization of medicines in the fields of cancer,
nephrology and inflammation. The company operates through a workforce of 17,000 employees.

Amgen reports its business under a single segment namely, Human Therapeutics. The key products offered under the
segment include Aranesp, Neulasta, NEUPOGEN, ENBREL and EPOGEN.

Aranesp is a novel erythropoiesis stimulating protein that stimulates red blood cell production while Neulasta is a
PEGylated protein that selectively stimulates the production of certain white blood cells (neutrophils). NEUPOGEN is a
recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF). It is a protein that helps in the production of
certain white blood cells including neutrophils. The company markets Aranesp, Neulasta and NEUPOGEN principally in
the US and Europe.

ENBREL is a Tumor Necrosis Factor (TNF) receptor fusion protein that stops binding TNF to TNF receptors to reduce
inflammation. EPOGEN is the company’s recombinant human erythropoietin product that stimulates red blood cell
production.

Amgen's other products include Sensipar (cinacalcet HCl), Nplate and Vectibix. Senispar is the company’s first small
molecule medicine that is utilized for the treatment of chronic kidney disease (CKD) in patients having parathyroid
hormone production in a large quantity (known as secondary hyperparathyroidism). Vectibix is the first entirely human
monoclonal antibody, which finds application in the treatment of patients that suffer from EGFr expressing metastatic
colorectal cancer. Nplate is the only platelet product approved by the US FDA for the treatment of adult chronic immune
thrombocytopenic purpura (ITP).

The company’s R&D activities are focused on the development of innovative novel human therapeutics in the fields of
inflammation, neuroscience, oncology and hematology, general medicine and metabolic disorders. For the fiscal year
2009, Amgen spent USD 2,864 million on its R&D activities, about 19.6% of its total revenues. Amgen’s R&D centers are
located in the US, the UK, Australia, Mexico, Canada, Germany, India and Hong Kong.

The company’s commercial and clinical manufacturing facilities are located across the US, Puerto Rico and the
Netherlands. The company's manufacturing activities include commercial bulk manufacturing; commercial formulation, fill
and finish manufacturing; and clinical manufacturing.

The company offers its products to a diverse range of healthcare providers, which include physicians, dialysis centers,
hospitals and pharmacies. It also markets certain products directly to consumers through direct-to-consumer print and
television advertising. The company’s sales and marketing activities are principally carried out in the US, Europe and
Canada to support its existing products. Its distribution centers are located in Kentucky and California in the US and in the
Netherlands.

Amgen operates through three wholly-owned subsidiaries, which include Washington-based Immunex Corporation;
Delaware-based Amgen USA Inc.; and Bermuda-based Amgen Manufacturing, Limited. Geographically, the company
classifies its operations into two regions namely, the US and Foreign Countries. For the fiscal year 2009, US accounted
for 78% of the company’s total revenues while Foreign Countries accounted for the remaining 22%.

Recently, the company submitted a Biologics License Application (BLA) to the US FDA for denosumab, a subcutaneous
RANK Ligand inhibitor that reduces skeletal related events in cancer patients.

Amgen also received the US FDA approval for risk evaluation and mitigation strategy (REMS) for erythropoiesis-
stimulating agents (ESAs), which include EPOGEN (Epoetin alfa), PROCRIT (Epoetin alfa) and Aranesp (darbepoetin
alfa). The company also launched a new website, www.amgenscholars.com that provides exclusive access to the online
Amgen Scholars Community.

Earlier, Amgen entered into an agreement with MedGenesis that provides worldwide license of glial cell line-derived
neurotrophic factor (GDNF) protein in CNS and non-CNS indications to MedGenesis. Amgen also entered into an
agreement with Array BioPharma Inc. for worldwide rights of Array's small-molecule glucokinase activator program. This
includes ARRY-403 that was tested in a Phase 1 clinical trial in patients with Type 2 diabetes.




___________________________________________________________________________________________

Amgen Inc. - SWOT Profile                                                                                           Page 3
Amgen Inc.

__________________________________________________________________________________________


Amgen Inc. - Major Products and Services

Amgen is a provider of human therapeutic products in the fields of supportive cancer care, nephrology, inflammation and
oncology. The company's key products include the following:

Amgen Inc., Major Products and Services
Products:

Erythropoietic Proteins

Human Anti-TNF (Tumor necrosis factor) Receptors

Recombinant Proteins

Oral Medication Products

Brands:

Nplate

Vectibix

Aranesp

ENBREL

EPOGEN

Neulasta

NEUPOGEN

Sensipar

Prolia
Source: Annual Report, Company Website, Primary and Secondary Research




___________________________________________________________________________________________

Amgen Inc. - SWOT Profile                                                                                       Page 4
Amgen Inc.

__________________________________________________________________________________________


Amgen Inc. - History

Amgen Inc., History

   Year               Event type                                                  Description


                                            The company collaborated with GlaxoSmithKline for commercializing Denosumab in
   2009    Contracts/Agreements
                                            Europe for Postmenopausal Osteoporosis (PMO) and Oncology indication.


                                            The company won two 2009 Scrip Awards, "Best Overall Pipeline" and "Best New
   2009    Corporate Awards
                                            Drug" for its product, Nplate (romiplostim) in London.


   2009    New Product Approvals            The company received marketing approval from the European Union (EU) for Nplate.


   2008    Contracts/Agreements             The company entered into an agreement with Biovitrum AB.


                                            The company entered        into   a    licensing    agreement   with 
								
To top